Regenerative Biologics
for Ocular Surface
Restoration

Severe dry eye disease — particularly aqueous-deficient dry eye from Sjögren’s syndrome, primary lacrimal gland disease, and GVHD — represents the most prevalent indication for biologic ophthalmic drops. The tear film deficiency not only dehydrates the ocular surface but deprives corneal epithelium of its physiological growth factor supply (EGF, vitamin A, fibronectin). Conventional tears replace volume without replacing biology.

The evidence hierarchy for severe ADDE biologics is: cord blood serum (highest growth factor concentration, superior to autologous serum in comparative RCTs) ≥ autologous serum (well-established Level I evidence, endorsed by TFOS DEWS II) ≥ PRP drops (emerging comparative data, higher PDGF-BB concentration than serum) > amniotic membrane devices (for acute flare management and refractory cases). The choice between CBS and AS is governed by availability, patient systemic status, and local regulatory/compounding constraints.

Neurotrophic keratitis (NK) is a rare but vision-threatening condition characterized by corneal hyposensitivity from trigeminal nerve damage — arising from herpetic keratitis, diabetes, multiple sclerosis, neurosurgical injury, or chemical burn. Without sensory nerve input, the corneal epithelium loses its neurotrophin supply (substance P, IGF-1) and fails to heal epithelial breaks — producing a progressive nonhealing defect that can deepen into stromal ulceration and perforation.

Biologic therapy for NK uniquely targets the neurotrophin deficiency: recombinant human nerve growth factor (cenegermin, Oxervate) is FDA-approved for NK — the first approved ophthalmic biologic specifically for this indication. Amniotic membrane provides complementary neurotrophin-analog activity and anti-inflammatory coverage. CBS eye drops provide exogenous NGF alongside EGF for combined neurotrophin and epithelial stimulation. The combination of cenegermin plus amniotic membrane is an emerging protocol for Mackie Stage 3 NK (corneal ulceration), though RCT data for the combination is not yet available.

Acute ocular chemical burns — particularly alkali burns from lime, cement, and ammonium compounds — represent ophthalmic emergencies where the time to biologic intervention directly predicts long-term visual prognosis. Grade III–IV burns with >50% limbal ischemia carry a high probability of LSCD, symblepharon, and permanent vision impairment without aggressive early biological intervention alongside standard management.

The Dua classification of limbal involvement guides biologic urgency: Grade I–II eyes may be managed with intensive topical therapy and delayed amniotic membrane; Grade III–IV eyes benefit from emergency amniotic membrane transplantation within 24–72 hours. Amniotic membrane applied as a graft covering the entire ocular surface (cornea and conjunctiva) simultaneously protects the limbal niche from further ischemic damage, provides anti-inflammatory cytokine delivery to suppress the acute inflammatory cascade, and furnishes structural coverage that prevents adhesion formation (symblepharon).

Pterygium excision is one of the most common anterior segment surgical procedures globally — with particular prevalence in tropical and subtropical regions where UV exposure drives pterygium formation. The recurrence problem is the central surgical challenge: bare sclera excision carries 30–80% recurrence, and recurrent pterygia are more aggressive and technically demanding to excise. Amniotic membrane transplantation reduces recurrence to 3–10% through its combined anti-fibrotic and anti-angiogenic mechanisms.

The practical decision between AMT and conjunctival autograft hinges on conjunctival tissue availability. AMT is specifically preferred when the superior bulbar conjunctiva must be preserved for future trabeculectomy, when bilateral pterygium requires staged excision (preserving donor tissue), and when the pterygium has significant subconjunctival involvement requiring extensive excision. The lyophilized format’s ambient storage allows operating room stocking without refrigeration logistics.

Trabeculectomy bleb failure from subconjunctival fibrosis is the primary cause of long-term surgical failure in glaucoma management. The fibrosis is driven by TGF-β1-mediated activation of subconjunctival Tenon’s fibroblasts at the bleb site — the same myofibroblast activation that amniotic membrane’s TGF-β3 and TSG-6 suppress in other contexts. Amniotic membrane as a surgical adjunct targets this failure mode without the serious risks associated with mitomycin C (hypotony, avascular bleb, endophthalmitis risk).

Applications in glaucoma surgery include: (1) primary trabeculectomy augmentation in high-risk cases (young age, previous conjunctival surgery, uveitic or neovascular glaucoma); (2) bleb needling revision with amniotic membrane injection at failed bleb sites; and (3) tube shunt patch graft to prevent conjunctival erosion over the tube. Prospective comparative data supports superior bleb survival with amniotic membrane vs. surgery alone in high-risk cases, without the serious safety profile of mitomycin C.

Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) produce severe acute and chronic ocular surface disease through immune-mediated conjunctival epithelial necrosis and progressive cicatrization. The acute phase (within 3 weeks of eruption onset) represents the critical window for biologic intervention — amniotic membrane coverage of the ocular surface during this window has been shown to significantly reduce long-term cicatrization severity and preserve limbal stem cell populations.

Prospective evidence demonstrates that amniotic membrane applied during the acute SJS phase (within 2–3 weeks of mucosal onset) reduces the severity of chronic sequelae including LSCD, symblepharon, and dry eye — a disease-course-modifying effect that no conventional treatment can replicate. Chronic SJS ocular disease management uses the same biologic toolkit as other cicatricial conditions: amniotic membrane for surface stabilization and anti-fibrotic coverage, CBS or AS drops for tear film supplementation, and LSCT with amniotic membrane substrate for established LSCD.

Post-refractive surgery complications — including delayed re-epithelialization after PRK/LASEK, diffuse lamellar keratitis (DLK) after LASIK, and recurrent epithelial erosion syndrome — represent a high-priority application for ophthalmic biologics given the patient expectation of perfect visual outcomes in an elective surgery population. Even minor delays in epithelial recovery produce patient dissatisfaction and visual instability.

PRP eye drops applied in the immediate post-PRK period (days 1–5) have been evaluated in prospective series, demonstrating faster epithelial closure (mean 0.8 days faster, p=0.03) and lower pain scores vs. conventional dressings. Amniotic membrane devices worn for 3–5 days post-PRK show similar findings. For recurrent corneal erosion syndrome — persistent epithelial loosening from inadequate stromal anchoring — amniotic membrane stromal support of the basement membrane provides structural stabilization alongside biological epithelial support.